Tempus AI, Inc. (NASDAQ:TEM) Given Average Recommendation of "Moderate Buy" by Analysts

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twelve research firms that are presently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $61.18.

Several research firms have commented on TEM. Wolfe Research lowered Tempus AI from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. JPMorgan Chase & Co. downgraded shares of Tempus AI from an "overweight" rating to a "neutral" rating and increased their price target for the stock from $50.00 to $55.00 in a report on Tuesday, February 25th. TD Cowen reaffirmed a "buy" rating and issued a $74.00 price objective (up previously from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Needham & Company LLC reissued a "buy" rating and set a $70.00 target price on shares of Tempus AI in a research note on Thursday. Finally, Guggenheim restated a "buy" rating on shares of Tempus AI in a research report on Tuesday, February 25th.

Insider Buying and Selling at Tempus AI

In other news, major shareholder Bradley A. Keywell sold 265,000 shares of the company's stock in a transaction on Friday, January 17th. The shares were sold at an average price of $35.10, for a total transaction of $9,301,500.00. Following the completion of the sale, the insider now owns 15,218,365 shares of the company's stock, valued at $534,164,611.50. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Wayne A.I. Frederick sold 3,000 shares of the firm's stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $45.54, for a total transaction of $136,620.00. Following the completion of the transaction, the director now directly owns 26,514 shares in the company, valued at approximately $1,207,447.56. This represents a 10.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,581,969 shares of company stock valued at $316,538,582 over the last quarter.

Remove Ads

Institutional Investors Weigh In On Tempus AI

Large investors have recently made changes to their positions in the stock. Operose Advisors LLC purchased a new position in Tempus AI during the fourth quarter worth approximately $25,000. Farther Finance Advisors LLC purchased a new position in shares of Tempus AI during the 4th quarter worth $34,000. Prestige Wealth Management Group LLC boosted its position in shares of Tempus AI by 910.4% during the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company's stock valued at $36,000 after acquiring an additional 965 shares during the last quarter. NewEdge Advisors LLC purchased a new stake in shares of Tempus AI in the fourth quarter valued at about $49,000. Finally, First Horizon Advisors Inc. increased its position in Tempus AI by 207.9% during the fourth quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company's stock worth $55,000 after purchasing an additional 1,108 shares during the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI Trading Up 4.5 %

Shares of TEM stock traded up $1.83 on Thursday, hitting $42.12. The company had a trading volume of 8,540,487 shares, compared to its average volume of 5,511,880. Tempus AI has a twelve month low of $22.89 and a twelve month high of $91.45. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The company has a 50-day moving average price of $56.19 and a 200-day moving average price of $50.91.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.